Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. (Q64891187)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. (English)

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

phase I clinical trial

1 reference

based on heuristic

inferred from title

Carsten Müller-Tidow

14

object named as

Carsten Müller-Tidow

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

author name string

Maria-Luisa Schubert

1

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Anita Schmitt

2

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Leopold Sellner

3

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Brigitte Neuber

4

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Joachim Kunz

5

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Patrick Wuchter

6

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Alexander Kunz

7

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Ulrike Gern

8

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Birgit Michels

9

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Susanne Hofmann

10

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Angela Hückelhoven-Krauss

11

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Andreas Kulozik

12

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Anthony D Ho

13

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Peter Dreger

15

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Michael Schmitt

16

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

publication date

19 May 2019

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

9

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

5

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

e026644

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumour lysis syndrome: new therapeutic strategies and classification

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current concepts in the diagnosis and management of cytokine release syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chimeric antigen receptor T cells for sustained remissions in leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postibrutinib outcomes in patients with mantle cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: Two case reports

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/31110096

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BMJOPEN-2018-026644

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

30 June 2019

http://europepmc.org/abstract/PMC/6530404

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64891187&oldid=2138403359"